Penn researchers announce results of Phase I trial using combretastatin drug

April 03, 2000

(Philadelphia, PA) -- New approaches are needed to treat solid malignant tumors that cannot be removed surgically and are resistant to traditional powerful chemotherapy drugs. In a Phase I clinical trial, a team of researchers at the University of Pennsylvania Cancer Center has found that patients with solid cancerous tumors were able to safely tolerate a new drug, originally derived from a South African willow bush, that interacts with the tumor's blood supply. James P. Stevenson, MD, assistant professor of medicine at Penn and lead author of the study, will present these findings at the 91st American Association of Cancer Research Meeting on Tuesday, April 4, 2000 in San Francisco.

Combretastatin A4 phosphate is a drug that is classified as a vascular targeting agent. It selectively targets and reduces or destroys blood vessels supplying malignant tumors while sparing the vasculature of normal tissues. Vascular targeting agents like combretastatin attack proliferating blood vessels that already exist, whereas angiogenesis inhibitors generally stop new blood vessels from developing.

In this study, 29 patients with a range of solid tumors, unresponsive to traditional chemotherapy, were treated with a daily intervenous dose of combretastatin for five consecutive days every three weeks. All of the patients were given CT scans before and at the end of the treatment cycle to determine changes in tumor blood supply. Nine patients who were given the highest dose of combretastatin were monitored via MRI. Dr. Stevenson's team found evidence of a decrease in blood flow to the tumor following combretastatin therapy in five of the nine patients who were followed by MRI.

"These early results are promising and suggest that combretastatin may affect tumor blood supply," says Stevenson. "We will continue investigating this drug for its potential benefits in fighting advanced cancers."

The University of Pennsylvania Cancer Center is one of only two sites in the country currently investigating this drug. The trial was sponsored by the drug manufacturer OXiGENE, in which Dr. Stevenson has no financial interest.
-end-
Editor's note: Dr. Stevenson can be reached during the AACR meeting by calling the press office. After the meeting, you can contact him by calling 215-349-5657.




University of Pennsylvania School of Medicine

Related Blood Vessels Articles from Brightsurf:

Biofriendly protocells pump up blood vessels
In a new study published today in Nature Chemistry, Professor Stephen Mann and Dr Mei Li from Bristol's School of Chemistry, together with Associate Professor Jianbo Liu and colleagues at Hunan University and Central South University in China, prepared synthetic protocells coated in red blood cell fragments for use as nitric oxide generating bio-bots within blood vessels.

Specific and rapid expansion of blood vessels
Upon a heart infarct or stroke, rapid restoration of blood flow, and oxygen delivery to the hypo perfused regions is of eminent importance to prevent further damage to heart or brain.

Flexible and biodegradable electronic blood vessels
Researchers in China and Switzerland have developed electronic blood vessels that can be actively tuned to address subtle changes in the body after implantation.

Lumpy proteins stiffen blood vessels of the brain
Deposits of a protein called ''Medin'', which manifest in virtually all older adults, reduce the elasticity of blood vessels during aging and hence may be a risk factor for vascular dementia.

Cancer cells take over blood vessels to spread
In laboratory studies, Johns Hopkins Kimmel Cancer Center and Johns Hopkins University researchers observed a key step in how cancer cells may spread from a primary tumor to a distant site within the body, a process known as metastasis.

Novel function of platelets in tumor blood vessels found
Scientists at Uppsala University have discovered a hitherto unknown function of blood platelets in cancer.

Blood vessels can make you fat, and yet fit
IBS scientists have reported Angiopoietin-2 (Angpt2) as a key driver that inhibits the accumulation of potbellies by enabling the proper transport of fatty acid into general circulation in blood vessels, thus preventing insulin resistance.

Brothers in arms: The brain and its blood vessels
The brain and its surrounding blood vessels exist in a close relationship.

Feeling the pressure: How blood vessels sense their environment
Researchers from the University of Tsukuba discovered that Thbs1 is a key extracellular mediator of mechanotransduction upon mechanical stress.

Human textiles to repair blood vessels
As the leading cause of mortality worldwide, cardiovascular diseases claim over 17 million lives each year, according to World Health Organization estimates.

Read More: Blood Vessels News and Blood Vessels Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.